



## **EVITRADE Announces Amendment to Artillery Labs Acquisition**

VANCOUVER, BC, October 29, 2018 – EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: EVAHF) (the “Company” or “Evitrade”) is pleased to announce that, further to its press release dated April 30, 2018, that it has signed an amending agreement for the acquisition of Artillery Holdings Ltd. (DBA Artillery Labs) (“Artillery”).

Pursuant to the definitive agreement Evitrade was to acquire all of the issued and outstanding common shares of Artillery in for an aggregate of 5 million common shares of Evitrade. Instead the Company will now enter into a Plan of Arrangement with Artillery and an Evitrade subsidiary to assist with Artillery’s development and its focus on marketing of health and wellness products.

In conjunction with the amending agreement Evitrade will be assigned a \$100,000 USD convertible note that it has acquired from a boutique investment and financing company as part of the amending settlement agreement for 450,000 shares issued at a deemed price of \$.30 and the cancellation of the balance of the 5 million shares held for the closing of the transaction.

Management of Evitrade believes the acquisition will further continue to enhance Evitrade’s business and commercialization strategies.

### ***For more information, please contact:***

C.K. Cheung, CEO & Director  
EVITRADE Health Systems Corporation  
Email [info@evahealthsystems.com](mailto:info@evahealthsystems.com)  
Website <http://www.evahealthsystems.com>  
CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp> US OTC  
Markets (OTCQB): <http://www.otcmarkets.com/stock/EVAHF/news>

### **About EVITRADE Health (CSE: EVA, OTCQB: EVAHF)**

*EVITRADE Health Systems Corp. (formerly Auxellence Health Corp.), is a Technology company specializing in the Life Sciences sector looking to deliver effective health solutions with a higher degree of predictability and consistency. The Company is focused in four main areas, Autonomous Medical Care, Molecular Biology, Nutraceutical Solutions and Genetic Selection. Through its Focus on Autonomous Medical Care, the Company offers a physiologically interactive computing platform that integrates medical devices and artificial intelligence applications into a fully automated, personal health management system for various chronic conditions.*

### **About Artillery**

*Artillery has been active in the online marketing various health and wellness products since 2015. In addition to its varied and encompassing digital marketing capabilities, Artillery has a portfolio of brands that it has developed and been successful with over the past several years.*

### **Forward Looking Statements; Disclaimers**

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The Company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which are posted on [www.sedar.com](http://www.sedar.com), <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>, and <https://www.otcmarkets.com/stock/EVAHF/news>, respectively. This news release does not constitute an offer to

sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.